AstraZeneca has welcomed the move, saying flexibility to extend the time between doses is the best strategy for the shot.
The results, gathered from trials in Britain, Brazil and SA, indicated some protection was given after one shot and immune responses were boosted with a longer interval to the second dose among participants aged 18 to 55 years.
“Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 after vaccination was 76%, and modelled analysis indicated protection did not wane during this initial three month period,” Oxford academics said.
The paper said vaccine efficacy was 82.4% with 12 or more weeks to the second dose, compared to 54.9% for those where the booster was given under six weeks after the first dose.